
Dita Maixnerova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5617990/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1099-1108.	0.4	24
2	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. Journal of Clinical Medicine, 2022, 11, 2810.	1.0	15
3	Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation. Frontiers in Immunology, 2021, 12, 726215.	2.2	9
4	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2021, 37, 42-52.	0.4	36
5	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.4	66
6	Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?. Journal of Nephrology, 2020, 33, 307-316.	0.9	14
7	Emerging Modes of Treatment of IgA Nephropathy. International Journal of Molecular Sciences, 2020, 21, 9064.	1.8	21
8	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	7
9	Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS ONE, 2019, 14, e0212254.	1.1	29
10	Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2019, 34, 587-596.	0.4	19
11	FP275A BIOMARKER OF COLLAGEN TYPE III DEGRADATION DECREASES WITH INCREASING FIBROSIS IN THE KIDNEY OF PATIENTS WITH IgA NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i124-i124.	0.4	1
12	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatric Nephrology, 2017, 32, 139-150.	0.9	71
13	Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. Disease Markers, 2016, 2016, 1-9.	0.6	21
14	Markers for the progression of IgA nephropathy. Journal of Nephrology, 2016, 29, 535-541.	0.9	66
15	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron, 2016, 132, 15-24.	0.9	60
16	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994–2011. Journal of Nephrology, 2015, 28, 39-49.	0.9	55
17	lgA Nephropathy in Czech Patients - Are We Able Reliably Predict the Outcome?. Kidney and Blood Pressure Research, 2014, 39, 555-562.	0.9	9
18	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	9.4	505

DITA MAIXNEROVA

#	Article	IF	CITATIONS
19	The coincidence of IgA nephropathy and Fabry disease. BMC Nephrology, 2013, 14, 6.	0.8	15
20	The retrospective analysis of 343 Czech patients with IgA nephropathyone centre experience. Nephrology Dialysis Transplantation, 2012, 27, 1492-1498.	0.4	29
21	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genetics, 2012, 8, e1002765.	1.5	301
22	Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrology Dialysis Transplantation, 2011, 26, 573-579.	0.4	15
23	Treatment of Lupus Nephritis with Cyclosporine – An Outcome Analysis. Kidney and Blood Pressure Research, 2007, 30, 124-128.	0.9	20
24	A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrology Dialysis Transplantation, 2006, 22, 179-186.	0.4	64
25	Silica and Asbestos Exposure in ANCA-Associated Vasculitis with Pulmonary Involvement. Renal Failure, 2005, 27, 605-608.	0.8	34